Scientists and clinicians at UCL and Great Ormond Street Hospital (GOSH) studying the effectiveness of CAR T-cell therapies in children with leukaemia, have discovered a small sub-set of T-cells that are likely to play a key role in whether the treatment is successful. Researchers say that stem cell memory T-cells… Read More
Researchers have developed an effective vaccine that re-engineers cells from a patient’s tumour to target and destroy cancer cells. The results, published in the peer-reviewed Journal of Clinical Oncology, show that 45% of patients treated with an autologous cell vaccine, created from their own cancer cells, had a confirmed anti-tumour… Read More
Flow Eighteen38, FairJourney Biologics (FJB) and the Hubrecht Institute are working together to harness the potential of FJB’s proprietary llama naïve libraries to develop antibodies for research tools for the group Hans Clevers. The Clevers group is studying molecular mechanisms of tissue development and cancer of various organs using organoids… Read More
Mount Sinai researchers have found that a widely available and inexpensive drug targeting inflammatory gene has reduced morbidity and mortality in mice infected with SARS-CoV-2. In a study published in Cell, the team reported that the drug, topotecan (TPT), inhibited the expression of inflammatory genes in the lungs of mice… Read More
Lytix Biopharma has announced promising full data results from a Phase I study of its lead candidate LTX-315 lysing solid tumours, which have been published in Clinical Cancer Research. The study was an open-label multicentre study of LTX-315 with multiple intralesional injections in patients with solid tumours for whom alternative… Read More
Andy Carr, Business Development Manager at The Institute of Cancer Research, London, introduces the new Innovation Gateway at The London Cancer Hub in Sutton, south London, to DDW’s Megan Thomas. MT: I understand the establishment of the Innovation Gateway is underway. What is the progress and when is it due… Read More
The Janssen Pharmaceutical Companies of Johnson & Johnson has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of cilta-cel, an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients with relapsed and/or refractory multiple myeloma. Read More
A new collaboration between Roswell Park Comprehensive Cancer Center and University of Rochester’s Wilmot Cancer Institute will help oncologists learn whether black and white cancer patients respond differently to immunotherapy treatment and seeks to improve the safety and effectiveness of these newer drugs in diverse populations. Funded by a two-year,… Read More
In a study by Yale Cancer Centre, researchers report on the discovery of a new role for STimulator of INterferon Genes, or STING. STING has traditionally been implicated in the immune response to DNA damage, however, in this study, the focus is on STING’s role in the tumour DNA damage… Read More
Francis Crick Institute group leader Karen Vousden has been awarded the first Pezcoller-Marina Larcher Fogazzaro-EACR Women in Cancer Research Award. This new award celebrates a researcher who has demonstrated academic excellence and achievements in the field of cancer research and who has, through leadership or by example, furthered the advancement… Read More
New research has uncovered an unexpected role for so-called “jumping” genes that are a source of genetic mutations responsible for many human diseases. In the new study from Children’s Medical Centre Research Institute at UT Southwestern (CRI), scientists discovered that these DNA sequences, also known as transposons, can protect against… Read More
Early results show that a new combination drug therapy is safe and effective against advanced skin cancer in patients who were unable to have their tumours surgically removed. Researchers say that the drug combination is among the first to demonstrate the potential value of a live common cold virus, a… Read More
Kancera, a company developing a new class of drugs for the treatment of inflammation and cancer, has reported preclinical research results, which show that the company’s Fractalkine blockers have the potential to disrupt cancer cells’ resistance to chemotherapy and thereby significantly improve the treatment of advanced cancer such as ovarian… Read More
The establishment of Innovation Gateway, a high-quality incubator space for life-science companies at The London Cancer Hub in Sutton, is underway. This is a significant step in realising the aims of The London Cancer Hub, a partnership between the London Borough of Sutton and The Institute of Cancer Research, that… Read More
Exscientia, an artificial intelligence (AI)-driven pharmatech company, has announced the first AI-designed molecule for immuno-oncology to enter human clinical trials, a joint venture co-invented and developed by Exscientia and Evotec. The A2a receptor antagonist, which is in development for adult patients with advanced solid tumours, includes the application of Exscientia’s… Read More
Researchers at the Francis Crick Institute have found that blocking a specific protein could increase tumour sensitivity to treatment with PARP inhibitors. Their work published in Science suggests combining treatments could lead to improved therapy for patients with inheritable breast cancers. Some cancers, including certain breast, ovarian and prostate tumours,… Read More
